| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM197709292971302 |
| P953 | full work available at URL | http://www.nejm.org/doi/pdf/10.1056/NEJM197709292971302 |
| P698 | PubMed publication ID | 408682 |
| P50 | author | Helena Käyhty | Q111990066 |
| P2093 | author name string | Peltola H | |
| Sarna S | |||
| Karanko V | |||
| Herva E | |||
| Renkonen OV | |||
| Pettay O | |||
| Mäkelä H | |||
| Sivonen A | |||
| Ahvonen P | |||
| Hällström K | |||
| Jousimies H | |||
| P2860 | cites work | PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES | Q24681118 |
| Archives roumaines de pathologie experimentales et de microbiologie | Q27709182 | ||
| Prevention of Meningococcal Disease by Group C Polysaccharide Vaccine | Q34225615 | ||
| Immunization of Humans with Polyribophosphate, the Capsular Antigen of Hemophilus influenzae, Type b | Q35896721 | ||
| Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants | Q35901911 | ||
| Identification of an Epidemic Strain of Group C Neisseria meningitidis by Bactericidal Serotyping | Q38517389 | ||
| Effect of group-A meningococcal vaccine in army recruits in Finland | Q39354729 | ||
| Vaccination against meningococcal group A disease in Finland 1974-75 | Q40893117 | ||
| Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state | Q42834013 | ||
| Immunogenicity of group A and group C meningococcal polysaccharides in human infants | Q67269150 | ||
| The survival time for different bacteria in various transport media | Q68734363 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | polysaccharide | Q134219 |
| vaccine | Q134808 | ||
| P304 | page(s) | 686-691 | |
| P577 | publication date | 1977-09-01 | |
| 1977-09-29 | |||
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age | |
| Clinical Efficacy of Meningococcus Group A Capsular Polysaccharide Vaccine in Children Three Months to Five Years of Age | |||
| P478 | volume | 297 |
| Q38556070 | "Love's labours lost": failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa |
| Q35922578 | A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt |
| Q52109354 | A thymus-independent (type 1) phosphorylcholine antigen isolated from Trichinella spiralis protects mice against pneumococcal infection. |
| Q40182351 | Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens |
| Q33754255 | Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine |
| Q72537586 | Age-distribution of meningococcal disease as predictor of epidemics |
| Q101226357 | Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management |
| Q36265032 | Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years |
| Q91466956 | Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials |
| Q41516117 | Antibody levels to Bordetella pertussis and Neisseria meningitidis in immunodeficient patients receiving immunoglobulin replacement therapy |
| Q37022545 | Antibody response to serogroup A and C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy |
| Q37021160 | Antigenic mimicry of a human cellular polypeptide by Mycoplasma hyorhinis |
| Q48761076 | Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis |
| Q42234518 | Avidity of IgG antibodies against meningococcal serogroup a polysaccharide and correlations with bactericidal activity in sera from meningitis patients and controls from Ethiopia |
| Q38870793 | Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine |
| Q40154927 | Bacterial meningitis—1982 |
| Q48138824 | Bioengineered polyester beads co-displaying protein and carbohydrate-based antigens induce protective immunity against bacterial infection |
| Q40215963 | Capsular polysaccharide vaccines today |
| Q36181172 | Capsular polysaccharide-protein conjugate vaccines and intravenous immunoglobulins |
| Q40794327 | Childhood bacterial meningitis: initial symptoms and signs related to age, and reasons for consulting a physician |
| Q37872958 | Comparative effects of carrier proteins on vaccine-induced immune response |
| Q44224966 | Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis |
| Q33846773 | Comparison of counter-current immunoelectrophoresis, latex agglutination, and radioimmunoassay in detection of soluble capsular polysaccharide antigens of Haemophilus influenzae type b and Neisseria meningitidis of groups A or C |
| Q37327673 | Comparison of passive hemagglutination, bactericidal activity, and radioimmunological methods in measuring antibody responses to Neisseria meningitidis group A capsular polysaccharide vaccine. |
| Q33591509 | Conjugated polysaccharide vaccines |
| Q44277367 | Conjugation of meningococcal lipooligosaccharides through their lipid A terminus conserves their inner epitopes and results in conjugate vaccines having improved immunological properties |
| Q34002209 | Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis |
| Q70885899 | Control of Infection and Techniques of Isolation in the Pediatric Intensive Care Unit |
| Q46630320 | Control of epidemic meningococcal meningitis by mass vaccination. II. Persistence of antibody four years after vaccination |
| Q69023947 | Control of meningococcal epidemics |
| Q73176811 | Control of serogroup C meningococcal meningitis by mass vaccination in Catalonia (Spain) |
| Q37750121 | Correlates of protection induced by vaccination |
| Q27008338 | Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine |
| Q39514347 | Current status--meningococcal vaccine |
| Q27025703 | Designing vaccines for the twenty-first century society |
| Q28397047 | Development and Evaluation of a Multiplex Microsphere Assay for Quantitation of IgG and IgA Antibodies against Neisseria meningitidis Serogroup A, C, W, and Y Polysaccharides |
| Q87176349 | Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths |
| Q37014845 | Development and evaluation of a tetraplex flow cytometric assay for quantitation of serum antibodies to Neisseria meningitidis serogroups A, C, Y, and W-135 |
| Q33601899 | Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers |
| Q34133149 | Development of natural immunity to Neisseria meningitidis |
| Q41099240 | Developments in childhood immunization |
| Q43080129 | Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people |
| Q71649412 | Effect of Neisseria meningitidis group A polysaccharide vaccine on nasopharyngeal carrier rates |
| Q37036581 | Effect of subgingival scaling on systemic antibody responses to oral microorganisms |
| Q43932679 | Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003. |
| Q35193487 | Evolution of conjugate vaccines |
| Q41442448 | Evolution of the subclass of IgG antibody to type 3 pneumococcal polysaccharide during childhood |
| Q37057019 | Experimental meningococcal infection in mice: a model for mucosal invasion |
| Q46976690 | Failure of meningococcal vaccination to stop the transmission of meningococci in Nigerian schoolboys |
| Q71245704 | Functional relationships of the genetic locus encoding the glycosyltransferase enzymes involved in expression of the lacto-N-neotetraose terminal lipopolysaccharide structure in Neisseria meningitidis |
| Q39666368 | Further characterization of responses of infants and children to meningococcal A polysaccharide vaccine |
| Q38044755 | Glycoconjugate vaccines. |
| Q67312787 | Group A Meningococcal Polysaccharide Vaccine and Course of the Group A Meningococcal Epidemic in Finland |
| Q72496295 | Guidelines for control of meningococcal disease. Laboratory Centre for Disease Control. Canadian Consensus Conference on Meningococcal Disease |
| Q68069468 | Guidelines for controlling meningococcal disease |
| Q41966979 | Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection |
| Q38011311 | History of meningococcal vaccines and their serological correlates of protection |
| Q38944335 | Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays |
| Q40893430 | Human T-cell response to meningococcal immunoglobulin A1 protease associated alpha-proteins |
| Q33751297 | Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine. |
| Q37042683 | Human opsonins to meningococci after vaccination. |
| Q33867340 | Humoral immune responses to Neisseria meningitidis in children |
| Q36231457 | Identification of T cell epitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis |
| Q71547320 | Immune response to meningococcal vaccines |
| Q70637745 | Immunisation against bacterial meningitis |
| Q40114251 | Immunization Against Infectious Diseases: Practice and Problems |
| Q84539641 | Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults |
| Q42082720 | Immunogenicity of meningococcal ACYW135 polysaccharide vaccine in Saudi children 5 to 9 years of age. |
| Q60469320 | Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years |
| Q34189898 | Incidence and prognosis of central nervous system infections in a birth cohort of 12,000 children |
| Q71512369 | Indications for use of meningococcal vaccine |
| Q39745445 | Infections in day-care centers |
| Q80816763 | Invasive infections caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae among children in St Petersburg, Russia |
| Q37256135 | Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults |
| Q43752926 | Investigator's anaemia |
| Q36838227 | Issues surrounding standardization of meningococcal group W135 serology |
| Q92883421 | Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants |
| Q37878485 | Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy |
| Q38340301 | Measurement of the human immune response to meningococcal lipooligosaccharide antigens by using serum to inhibit monoclonal antibody binding to purified lipooligosaccharide |
| Q58423302 | Meningococcal Vaccines |
| Q34760360 | Meningococcal disease in Scandinavia |
| Q36258316 | Meningococcal disease in South Australia: incidence and serogroup distribution 1971-1980 |
| Q35055030 | Meningococcal disease: treatment and prevention |
| Q35194824 | Meningococcal glycoconjugate vaccines. |
| Q35643952 | Meningococcal immunology |
| Q37058833 | Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. |
| Q37669413 | Meningococcal serogroup B vaccines: Estimating breadth of coverage |
| Q34482078 | Meningococcal serogroup C conjugate vaccine |
| Q54265841 | Meningococcal vaccination in pregnancy. |
| Q34218569 | Meningococcal vaccines |
| Q80511370 | Meningococcal vaccines |
| Q66701047 | Meningococcal vaccines and disease due to other serogroups |
| Q40864279 | Meningococcal vaccines. Current status and future possibilities |
| Q41260238 | Meningococcemia |
| Q40259735 | Meningococci |
| Q41390986 | Meningococcus group A vaccine in children three months to five years of age. Adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide |
| Q33767903 | Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine. |
| Q38881421 | Naturally-acquired immunity to Neisseria meningitidis group A. |
| Q37878480 | New frontiers in meningococcal vaccines |
| Q42982220 | One Flu Over the Cuckoo's Nest |
| Q36689674 | Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine |
| Q73145906 | Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein |
| Q30210120 | Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel |
| Q39737089 | Perspectives on occult bacteremia in children |
| Q34128272 | Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation |
| Q39699553 | Polysaccharide Meningococcal Vaccines—Current Status |
| Q24244832 | Polysaccharide vaccines for preventing serogroup A meningococcal meningitis |
| Q33908993 | Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. |
| Q50129705 | Potential and limitations of polysaccharide vaccines in infancy |
| Q53701548 | Potential targets for next generation anti-microbial glycoconjugate vaccines. |
| Q35801994 | Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice |
| Q40184073 | Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines |
| Q37111150 | Preparation and physicochemical and immunological characterization of polysaccharide-outer membrane protein complexes of Neisseria meningitidis |
| Q34260060 | Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis |
| Q24676339 | Preventative strategies on meningococcal disease |
| Q54255446 | Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development. |
| Q35115426 | Prophylaxis in bacterial meningitis |
| Q33724705 | Prophylaxis of bacterial meningitis |
| Q37354401 | Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa |
| Q36674549 | Prospects for the prevention of bacterial meningitis with polysaccharide vaccines |
| Q24537338 | Prospects for vaccine prevention of meningococcal infection |
| Q34094054 | Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model |
| Q40792174 | Protective activity of Vi capsular polysaccharide vaccine against typhoid fever |
| Q33797264 | Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children |
| Q40708233 | Reactogenicity and safety of meningococcal A and C vaccine in Saudi children |
| Q36065978 | Recent developments in Neisseria meningitidis group A conjugate vaccines |
| Q39507497 | Relationship between serum bactericidal activity and serogroup-specific immunoglobulin G concentration for adults, toddlers, and infants immunized with Neisseria meningitidis serogroup C vaccines |
| Q36106717 | Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis |
| Q36342003 | Safety and immunogenicity of a group 29E meningococcal capsular polysaccharide vaccine in adults |
| Q36431574 | Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults |
| Q34533811 | Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. |
| Q80390726 | Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults |
| Q41021466 | Salivary Functional Antibody Secretion Is Reduced in Older Adults: A Potential Mechanism of Increased Susceptibility to Bacterial Infection in the Elderly |
| Q53762383 | Salivary and Serum Antibody Response Against Neisseria meningitidis After Vaccination With Conjugate Polysaccharide Vaccines in Ethiopian Volunteers. |
| Q35648260 | Serologic correlates of protection for evaluating the response to meningococcal vaccines |
| Q33769150 | Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. |
| Q34606343 | Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008 |
| Q35783511 | Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7 |
| Q38549601 | Serum bactericidal antibody assays - The role of complement in infection and immunity |
| Q44075323 | Serum opsonins to serogroup B meningococci in meningococcal disease |
| Q72533052 | Shift in the age-distribution of meningococcal disease as predictor of an epidemic? |
| Q35229074 | Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. |
| Q91749966 | Standing on the shoulders of giants: two centuries of struggle against meningococcal disease |
| Q64362426 | Statement on meningococcal vaccination for travellers. Committee to Advise on Tropical Medicine and Travel |
| Q43796650 | Status of a group B Neisseria meningitidis vaccine |
| Q36992911 | T-cell modulation of the murine antibody response to Neisseria meningitidis group A capsular polysaccharide |
| Q36504440 | Targeted vaccination with meningococcal polysaccharide vaccine in one district of the Czech Republic |
| Q64904695 | Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. |
| Q64108196 | The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology |
| Q44302360 | The effect of polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal carriage of Streptococcus pneumoniae |
| Q39186214 | The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines |
| Q33626434 | The meningococcus and mechanisms of pathogenicity |
| Q69879835 | The status of vaccines to meningococcal and gonococcal disease |
| Q44017120 | Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children |
| Q53912328 | Treatment and prevention of meningococcal disease. |
| Q33889550 | Update on Haemophilus influenzae serotype b and meningococcal vaccines |
| Q33812435 | Update on meningococcal disease with emphasis on pathogenesis and clinical management |
| Q24533456 | Use of licensed vaccines for active immunization of the immunocompromised host |
| Q34460367 | Vaccine prevention of meningococcal disease, coming soon? |
| Q34203615 | Vaccine trials. |
| Q30771493 | Vaccines against meningococcal disease: current and future technologies |
| Q69198474 | Vaccines for prevention of meningococcal disease |
| Q39790912 | Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future |
| Q66701201 | Who Should be Given Meningococcal Vaccine? |
| Q74289437 | [Analysis of the management of the vaccination campaign in 1996-1997 against meningococcus C in Galicia] |
| Q77367323 | [Meningococcal C disease epidemic in Galicia 1996: the decision making process] |
| Q42982364 | Vol au-dessus d'un nid de coucous |
Search more.